|
[Related PubMed/MEDLINE]
Total Number of Papers: 21
|
|
|
|
|
[Display Entries]
|
| |
|
[Entries Per Page]
|
|
per page
|
| |
|
Page Control
|
|
|
|
Page: of
|
|
|
|
| Abbreviation |
: GPs |
| Long Form |
: Gypenosides |
|
| No. |
Year |
Title |
Co-occurring Abbreviation |
| 1 |
2022 |
Gypenosides Prevent and Dissolve Cholesterol Gallstones by Modulating the Homeostasis of Cholesterol and Bile Acids. |
12alpha-OH, ABC, BAs, CG, GO, KEGG, LD |
| 2 |
2021 |
Gypenosides Inhibit Inflammatory Response and Apoptosis of Endothelial and Epithelial Cells in LPS-Induced ALI: A Study Based on Bioinformatic Analysis and in vivo/vitro Experiments. |
ALI, DEGs, GO, KEGG |
| 3 |
2021 |
[Study on effect of gypenosides on insulin sensitivity of rats with diabetes mellitus via regulating NF-kappaB signaling pathway]. |
CRP, FBG, GLUT4, HOMA-IR, IL-1beta, IL-6, ISI, NF-kappaB, p-Akt, p-IkappaBalpha, p-IRS-1, p-p65, T2DM, TNF-alpha, Tyr |
| 4 |
2019 |
Formulation design, characterization, and in vitro and in vivo evaluation of nanostructured lipid carriers containing a bile salt for oral delivery of gypenosides. |
NLCs |
| 5 |
2018 |
Gypenosides as natural emulsifiers for oil-in-water nanoemulsions loaded with astaxanthin: Insights of formulation, stability and release properties. |
AST |
| 6 |
2018 |
Gypenosides attenuate lipopolysaccharide-induced neuroinflammation and anxiety-like behaviors in rats. |
BDNF, IL-1beta, IL-6, LPS, NF-kappaB, TLR4 |
| 7 |
2018 |
Gypenosides Attenuate Lipopolysaccharide-Induced Neuroinflammation and Memory Impairment in Rats. |
BDNF, IL-1beta, IL-6, iNOS, LPS, NF-kappaB, TLR4 |
| 8 |
2018 |
Gypenosides attenuate lipopolysaccharide-induced optic neuritis in rats. |
GFAP, LPS, NF-kappaB, RGCs, STAT |
| 9 |
2018 |
Gypenosides improve diabetic cardiomyopathy by inhibiting ROS-mediated NLRP3 inflammasome activation. |
CRPs, DCM, HG, ROS |
| 10 |
2017 |
Gypenosides Ameliorate Carbon Tetrachloride-Induced Liver Fibrosis by Inhibiting the Differentiation of Hepatic Progenitor Cells into Myofibroblasts. |
AST, CK19, Col I, HPCs |
| 11 |
2017 |
Gypenosides ameliorate memory deficits in MPTP-lesioned mouse model of Parkinson's disease treated with L-DOPA. |
CREB, L-DOPA, MPTP, NMDA, PD, TH |
| 12 |
2017 |
Gypenosides Inhibits Xanthine Oxidoreductase and Ameliorates Urate Excretion in Hyperuricemic Rats Induced by High Cholesterol and High Fat Food (Lipid Emulsion). |
ADA, FEUA, GDA, LE, SCr, SUA, UA, UCr, uUA, XDH, XOD |
| 13 |
2015 |
Gypenosides attenuate the development of L-DOPA-induced dyskinesia in 6-hydroxydopamine-lesioned rat model of Parkinson's disease. |
L-DOPA, LID, PD |
| 14 |
2015 |
Mechanism of action of gypenosides on type 2 diabetes and non-alcoholic fatty liver disease in rats. |
ALT, AST, BG, CYP450, PPARgamma, T2DM-NAFLD, TC, TG |
| 15 |
2014 |
Gypenosides attenuate cholesterol-induced DNA damage by inhibiting the production of reactive oxygen species in human umbilical vein endothelial cells. |
--- |
| 16 |
2014 |
Gypenosides protected the neural stem cells in the subventricular zone of neonatal rats that were prenatally exposed to ethanol. |
FASD, NSCs, SVZ |
| 17 |
2013 |
Gypenosides pre-treatment protects the brain against cerebral ischemia and increases neural stem cells/progenitors in the subventricular zone. |
GFAP, MCAO, NSCs, SVZ |
| 18 |
2013 |
The immunological adjuvant activity of gypenosides liposome against Newcastle disease vaccine. |
BL, GPSL, ND |
| 19 |
2010 |
Gypenosides inhibit renal fibrosis by regulating expression of related genes in rats with unilateral ureteral obstruction. |
CTGF, TGF-ss1, UUO |
| 20 |
2010 |
Gypenosides protects dopaminergic neurons in primary culture against MPP(+)-induced oxidative injury. |
PD, TH |
| 21 |
2006 |
Gypenosides protect primary cultures of rat cortical cells against oxidative neurotoxicity. |
gamma-GCS, GR |
|
A Search Service for Abbreviation / Long Form
